Evolus Inc is engaged in providing physicians and their patients with expanded choices in medical aesthetic treatments and procedures. Its product candidate is an injectable formulation of a 900 kDa Botulinum toxin Type A complex.
$11.61 -0.61 (-4.99%)
As of 03/05/2021 15:58:54 EST IEX book CBOE book
2021 © Stock Market MBA, Inc.